Pharma - STAT

Pharmalot

Pharma leaders shoot down WHO voluntary pool for patent rights on Covid-19 products

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo aims for 1 billion doses of a Covid-19 vaccine booster; Pence aide holds lots of pharma stocks

By Ed Silverman

Pharmalot

FDA finds ‘unacceptable’ levels of a possible carcinogen in a widely used diabetes pill

By Ed Silverman

Pharmalot

Medical societies have ‘extensive’ financial ties with drug and device makers

By Ed Silverman

Pharmalot

Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy

By Ed Silverman

Pharmalot

Pharmalittle: Moderna executives cashed out big time; should we have ‘quality scores’ for manufacturing drugs?

By Ed Silverman

Pharmalot

Experts push for a ‘seal of approval’ to improve the quality of medicines

By Ed Silverman

Pharmalot

A pharma effort to work with European officials to develop needed drugs is a ‘failure’

By Ed Silverman

Pharmalot

Pharmalittle: Merck enters Covid-19 vaccine race; pharma alarmed by push for U.S.-only supply chain

By Ed Silverman

Business

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

By Elizabeth Cooney

Pharmalot

First generic version of Gilead’s remdesivir will be sold by a Bangladesh drug maker

By Ed Silverman

Pharmalot

Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study

By Ed Silverman

Pharmalot

In a tale of two Mercks, the German company wins a court battle over its U.S. rival

By Ed Silverman

Pharmalot

After years of manufacturing problems, Akorn files for bankruptcy protection

By Ed Silverman

Pharmalot

U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine

By Ed Silverman

Pharmalot

Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine

By Ed Silverman

Pharmalot

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

By Ed Silverman

Pharmalot

Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.

By Ed Silverman

Pharmalot

CEO tapped by Trump to make generic drugs during pandemic has a dicey track record

By Ed Silverman

Pharmalot

Pharmalittle: White House signs deal for U.S.-made generics to fight Covid-19; Gilead expands remdesivir donations

By Ed Silverman

Pharmalot

Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’

By Ed Silverman

Pharmalot

EMA urged to release full clinical trial data upon authorizing Covid-19 treatments

By Ed Silverman

Pharmalot

Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug

By Ed Silverman

Pharmalittle: Fauci ‘didn’t like’ Moderna vaccine data release; Pfizer breast cancer drug suffers a setback

The WHO launched a voluntary Covid-19 product pool. What happens next?

Up and down the ladder: The latest comings and goings

Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit

Pharma leaders shoot down WHO voluntary pool for patent rights on Covid-19 products

Pharmalittle: Glaxo aims for 1 billion doses of a Covid-19 vaccine booster; Pence aide holds lots of pharma stocks

FDA finds ‘unacceptable’ levels of a possible carcinogen in a widely used diabetes pill

Medical societies have ‘extensive’ financial ties with drug and device makers

Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy

Pharmalittle: Moderna executives cashed out big time; should we have ‘quality scores’ for manufacturing drugs?

Experts push for a ‘seal of approval’ to improve the quality of medicines

A pharma effort to work with European officials to develop needed drugs is a ‘failure’

Pharmalittle: Merck enters Covid-19 vaccine race; pharma alarmed by push for U.S.-only supply chain

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

First generic version of Gilead’s remdesivir will be sold by a Bangladesh drug maker

Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

Up and down the ladder: The latest comings and goings

Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study

In a tale of two Mercks, the German company wins a court battle over its U.S. rival

After years of manufacturing problems, Akorn files for bankruptcy protection

U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine

Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.

CEO tapped by Trump to make generic drugs during pandemic has a dicey track record

Pharmalittle: White House signs deal for U.S.-made generics to fight Covid-19; Gilead expands remdesivir donations

Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’

EMA urged to release full clinical trial data upon authorizing Covid-19 treatments

Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug